Pharmacy World and Science

, Volume 26, Issue 5, pp 277–281 | Cite as

Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

  • David A.M.C. van de Vijver
  • Raymund A.C. Roos
  • Paul A.F. Jansen
  • Arijan J. Porsius
  • Anthonius de Boer


Introduction: Antiparkinsonian drugs can induce behavioural disturbances, which should be treated by first reducing antiparkinsonian drugs and/or starting a benzodiazepine. If this approach fails, then antipsychotics can be considered. The aim of this study was to determine how often antiparkinsonian drugs are decreased and benzodiazepines are started in levodopa users before start of an antipsychotic drug.

Methods: Data came from the PHARMO database, which includes drug dispensing records for all residents of six Dutch cities. All patients were selected who had started antipsychotic drug therapy at least 360 days later than, and 180 days before the earliest and the latest dispensing date for levodopa in PHARMO respectively. For each patient who started an antipsychotic drug we randomly selected 2 matched controls who used levodopa for at least 540 days and who did not start an antipsychotic. We determined how many persons had reduced antiparkinsonian drug treatment (i.e., dosage decrement or discontinuation of an antiparkinsonian agent) or had started a benzodiazepine in the 180 days before the start of the antipsychotic orbefore a randomly chosen index date in the controls.

Results: We identified 40 antipsychotic starters and 64 matched controls. The prescribed daily dose of antiparkinsonian drug treatment was reduced in 14 antipsychotic starters (37%) and in 17 controls prior to the index date (27%) (relative risk 1.27, 95% confidence interval 0.77-2.08). Of these, 2 antipsychotic starters (5%) and 5 controls (8%) had started with a benzodiazepine (relative risk 0.73; 0.22-2.96). A further 34 antipsychotic starters (85%) and 49 controls (77%) returned later than expected to their community pharmacy before the index date (relative risk 1.43; 0.70-2.96).

Conclusion: Our study demonstrates that the advice to reduce the levodopa dose or to start with a ben zodiazepine when behavioural disturbances occur during levodopa treatment prior to the start of an antipsychotic, is not followed in daily practice.

Antiparkinsonian drug Antipsychotic drugs Levodopa Parkinson’s disease Pharmacotherapy Pharmacy records 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cummings JL. Behavioural complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39: 708–16.PubMedGoogle Scholar
  2. 2.
    Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse ef-fects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging 1997, 10: 367–83.PubMedGoogle Scholar
  3. 3.
    Wolters EC, Francot CMJE. Mental dysfunction in Parkinson's disease. Parkinsonism and related disorders 1998; 4: 107–12.CrossRefGoogle Scholar
  4. 4.
    Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991; 84: 111–3.PubMedGoogle Scholar
  5. 5.
    Sanchez Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265–8.PubMedGoogle Scholar
  6. 6.
    Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Par-kinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733–45.Google Scholar
  7. 7.
    Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucina-tions induced by long-term drug therapy. Am J Psychiatry 1982; 139: 94–7.PubMedGoogle Scholar
  8. 8.
    Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56: S1–S88.Google Scholar
  9. 9.
    Eichhorn T, Moller J, Mrass G, Pohl M. Neuropsychiatric compli-cations of Parkinson's disease. In: Le Witt P, Oertel W, editors. Parkinson's Disease. The Treatment Options. London: Martin Dunitz, 1999: 51–62.Google Scholar
  10. 10.
    Quinn N. Drug treatment of Parkinson's disease. BMJ 1995; 310: 575–9.PubMedGoogle Scholar
  11. 11.
    Lau HS, de Boer A, Beuning KS, Porsius AJ. Validation of phar-macy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Heerdink ER, Leufkens HG, Koppedraaijer C, Bakker A. Informa-tion on drug use in the elderly: a comparison of pharmacy, gen-eral-practitioner and patient data. Pharm World Sci 1995; 17: 20–4.PubMedGoogle Scholar
  13. 13.
    Herings RMC. PHARMO: a record linkage system for postmar-keting surveillance of prescription drugs in the Netherlands [Dis-sertation]. Utrecht University, 1993: 207.Google Scholar
  14. 14.
    Commissie farmaceutische hulp. Farmacotherapeutisch kompas 2000/2001. In: van der Kuy A, editor. Amstelveen: College voor Zorgverzekeringen, 2000.Google Scholar
  15. 15.
    Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical an-tipsychotics in the treatment of schizophrenia: systematic over-view and meta-regression analysis. BMJ 2000; 321: 1371–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201–11.CrossRefPubMedGoogle Scholar
  17. 17.
    van de Vijver DAMC, Stricker BHC, Breteler MMB, Roos RAC, Porsius AJ, de Boer A. Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharm World Sci 2001; 23: 148–52.CrossRefPubMedGoogle Scholar
  18. 18.
    de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, Van der Meche FG et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 1995; 45: 2143–6.PubMedGoogle Scholar
  19. 19.
    Greenland S, Robins JM. Estimation of a common effect param-eter from sparse follow-up data. Biometrics 1985; 41: 55–68.PubMedGoogle Scholar
  20. 20.
    Willekens-Bogaers MA, Smits GW. Neuroleptics in psychogeriat-rics. Evaluation of a treatment proposal. Tijdschr Gerontol Geriatr 1990; 21: 99–107.PubMedGoogle Scholar
  21. 21.
    Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70–6.PubMedGoogle Scholar
  22. 22.
    van de Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, de Boer A. Start of antipsychotic drugs in new patients with Parkinson's disease. Pharmacoepidemiol Drug Saf 2001; 10 (Suppl 1) 20–1.CrossRefGoogle Scholar
  23. 23.
    The Parkinson Study Group. Low-dose clozapine for the treat-ment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63.Google Scholar
  24. 24.
    The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041–2.Google Scholar
  25. 25.
    Dewey Jr RB, O'Suilleabhain PE. Treatment of drug-induced psy-chosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000; 55: 1753–4.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • David A.M.C. van de Vijver
    • 1
  • Raymund A.C. Roos
    • 2
    • 3
  • Paul A.F. Jansen
    • 4
  • Arijan J. Porsius
    • 1
  • Anthonius de Boer
    • 1
  1. 1.Department of Pharmacoepidemiology and -therapy, Utrecht Institute for Pharmaceutical Sciences (UIPS)Utrecht UniversityUtrechtThe Netherlands
  2. 2.Department of neurologyLeiden UniversityThe Netherlands
  3. 3.Medical Centre (LUMC)Leiden UniversityLeidenThe Netherlands
  4. 4.Department of geriatric medicineUniversity Medical Centre Utrecht (UMCU), Utrecht UniversityUtrechtThe Netherlands

Personalised recommendations